A Phase 3 Study to Evaluate Safety and Biomarkers of Resmetirom (MGL-3196) in Non Alcoholic Fatty Liver Disease Patients

NCT04197479 · clinicaltrials.gov ↗

PHASE3

Phase

COMPLETED

Status

1343

Enrollment

INDUSTRY

Sponsor class

Conditions

Non-Alcoholic Fatty Liver Disease

Interventions

DRUG: Placebo
DRUG: Resmetirom

Sponsor

Madrigal Pharmaceuticals, Inc.